SCHEMBL5748508

SCHEMBL5748508

CCOC(=O)CSc1cc(F)ccc1[N+](=O)[O-]

nearest known ligand 0.56

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.53
ALDH1A1 P00352 3/20 0.53
GAA P10253 1/20 0.53
TDP1 Q9NUW8 4/20 0.52
PRNP P04156 1/20 0.44
USP2 O75604 1/20 0.44
KMT2A Q03164 2/20 0.43
MAPK1 P28482 2/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
ATM Q13315 1/20 0.42
LMNA P02545 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28608518 0.81 LMNA (0.52) MAPTALDH1A1GAATDP1KMT2A
SCHEMBL10964950 0.79 ALDH1A1 (0.48) MAPTALDH1A1GAATDP1KMT2A
SCHEMBL5147549 0.79 MAPT (0.50) MAPTALDH1A1GAATDP1USP2
SCHEMBL3065013 0.79 ALDH1A1 (0.50) MAPTALDH1A1GAATDP1USP2
SCHEMBL10985488 0.79 TDP1 (0.46) MAPTALDH1A1TDP1KMT2AMAPK1
SCHEMBL20563870 0.78 ALDH1A1 (0.49) MAPTALDH1A1TDP1PRNPKMT2A
SCHEMBL25376120 0.78 MAPT (0.46) MAPTALDH1A1GAATDP1USP2
SCHEMBL5802564 0.78 MAPT (0.62) MAPTALDH1A1GAATDP1KMT2A
SCHEMBL10473975 0.77 MAPT (0.50) MAPTALDH1A1TDP1KMT2AMAPK1
SCHEMBL28841208 0.77 ALDH1A1 (0.61) MAPTALDH1A1GAATDP1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1419155-B1 PIPERIDINE DERIVATIVES AS ANTIBACTERIAL AGENTS SMITHKLINE BEECHAM PLC (GB) 2006-11-08 EP disclosed
US-20040198756-A1 Medicaments SMITHKLINE BEECHAM PLC (GB) 2004-10-07 US disclosed
EP-1419155-A2 PIPERIDINE DERIVATIVES AS ANTIBACTERIAL AGENTS SMITHKLINE BEECHAM PLC (GB) 2004-05-19 EP disclosed
WO-2003010138-A2 PIPERIDINE DERIVATIVES AS ANTIBACTERIAL AGENTS SMITHKLINE BEECHAM PLC (GB) 2003-02-06 WO disclosed
EP-0462813-B1 Bicyclic pyran derivatives and their use as inhibitors of 5-lipoxygenase ZENECA LTD (GB) 1995-10-25 EP disclosed
US-5373007-A Lipoxygenase inhibitors ZENECA LIMITED (GB) 1994-12-13 US disclosed
US-5321025-A Inhibitors of 5-lipoxygenase IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1994-06-14 US disclosed
US-5217969-A Antiinflammatory, antiulcer agent IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1993-06-08 US disclosed
EP-0462813-A2 Bicyclic pyran derivatives and their use as inhibitors of 5-lipoxygenase ZENECA LIMITED (GB) 1991-12-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040198756-A1 Medicaments PIGO, PSAP, CD68 MAPT 4026/4885ALDH1A1 1066/4885GAA 716/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.